An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease

NCT00701129 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

4

Enrollment

INDUSTRY

Sponsor class

Conditions

Pompe Disease
Glycogen Storage Disease Type II

Interventions

BIOLOGICAL: Alglucosidase Alfa
DRUG: Methotrexate
DRUG: Rituximab

Sponsor

Genzyme, a Sanofi Company